Pan, Calvin |
NCT03476083: Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission |
|
|
| Recruiting | 4 | 280 | RoW | Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily., HBIg 200 IU im for infants in the group B, HBV vaccine 10 ug im for all infants | New Discovery LLC | Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia, Chronic Infection | 05/21 | 05/24 | | |
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides |
|
|
| Recruiting | 4 | 100 | RoW | Tenofovir Alafenamide 25 MG, Vemlidy | New Discovery LLC, Beijing Ditan Hospital | Hepatitis B, Chronic | 09/23 | 09/23 | | |
NCT04000737: YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 125 | US, RoW | YIV-906+Sorafenib, Placebo+Sorafenib | Yiviva Inc. | Advanced Hepatocellular Carcinoma | 12/23 | 05/24 | | |
NCT04211805: Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B |
|
|
| Recruiting | N/A | 450 | RoW | Tenofovir Alafenamide 25 MG for arm (A), HBIg 200 IU im for infants, HBV vaccine 10 ug im for infants, Tenofovir Disoproxil Fumarate 300mg for arm (B) | New Discovery LLC | Hepatitis B, Chronic, Pregnancy Related | 09/21 | 09/21 | | |
NCT06051669: Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US |
|
|
| Recruiting | N/A | 418 | US | iLivTouch, FibroScan | New Discovery LLC, NYU Langone Health, Stanford University, Rush University, Baylor University, Wuxi Hisky Medical Technology Co Ltd | Liver Fibrosis, Fatty Liver | 09/24 | 03/25 | | |